603233.SH
大参林
SSE · Healthcare · Biotechnology · CN
CNY 17.36
−1.70%Year over year
Reported trailing growth
- Revenue
- +3.1%
- EBITDA
- —
- EBIT
- +33.8%
- EPS
- +32.3%
- Free cash flow
- +69.0%
- Operating cash flow
- +24.7%
Forward estimates
Based on analyst estimates
- Revenue
- +16.4%
- EBITDA
- +65.3%
- EPS
- +13.9%
Three-year CAGR
- Revenue
- +9.0%
- EBITDA
- +8.4%
- EBIT
- +9.4%
- Net income
- +6.0%
- EPS
- +5.9%
- Free cash flow
- +21.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026